Chart-Typ:
Zeitraum:
| WELL Health Technologies Corp.: WELL Health Delivers Record Q1-2026 with Canadian Clinics Run Rate Exceeding $500M and Revenue Up 25% to $368M | WELL achieved quarterly revenues of $368.3 million in Q1-2026, an increase of 25% as compared to Q1-2025 driven by organic growth, acquisitions and the inclusion of HEALWELL results in WELL's consolidated... ► Artikel lesen |
| WELL Health Technologies Corp.: WELL Health to Announce First Quarter 2026 Financial Results on May 7, 2026 | Vancouver, British Columbia--(Newsfile Corp. - April 28, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively... ► Artikel lesen |
| WELL Health Technologies Corp.: WELL Health Reports Record Canadian Patient Visits and Primary Care Margin Expansion in Q1-2026 | WELL Canada delivered a record ~1.27 million patient visits(1) in Q1-2026, representing 33% year-over-year growth and 13% organic growth, reflecting broad-based strength across its national network.Primary... ► Artikel lesen |
| WeRide und Lenovo wollen gemeinsam 200.000 autonome Fahrzeuge auf die Straßen bringen | Der Computerhersteller Lenovo tut sich mit dem auf autonomes Fahren spezialisierten Anbieter WeRide zusammen. Ziel der Partnerschaft: In den kommenden fünf Jahren weltweit gemeinsam 200.000 autonome... ► Artikel lesen |
| WeRide, Lenovo Expand Partnership To Deploy 200,000 Autonomous Vehicles Globally | BEIJING (dpa-AFX) - WeRide Inc. (WRD) on Monday said it has expanded its collaboration with Lenovo to accelerate large-scale commercialization of Level 4 autonomous driving, with plans to deploy... ► Artikel lesen |
| WeRide Inc.: WeRide and Lenovo Collaborate to Deploy 200,000 Autonomous Vehicles Globally Over Five Years | BEIJING, April 27, 2026 (GLOBE NEWSWIRE) -- WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, announced an expanded collaboration with Lenovo (HKSE: 0992) at Auto China... ► Artikel lesen |
| Gyre Therapeutics Inc.: Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update | Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted... ► Artikel lesen |
| Gyre Therapeutics Inc.: Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company | Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory... ► Artikel lesen |
| Gyre Therapeutics Inc.: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CRUNCHFISH AB finden Sie auf Wallstreet Online.